Real-world effectiveness of CDK4/6i in first-line treatment of HR+/HER2- advanced/metastatic breast cancer: Updated systematic review

Researchers conducted an analysis of real-world evidence on the effectiveness of CDK4/6 inhibitors as first-line treatment of HR+ HER2- advanced/metastatic breast cancer. After reviewing 82 unique studies that evaluated overall and progression-free survival data for multiple CDK4/6 inhibitors, the researchers concluded that the real-world data demonstrated significant clinical benefits in this patient population.